Allworth Financial’s SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $32.1K | Hold |
790
| – | – | ﹤0.01% | 2204 |
|
2025
Q1 | $31.5K | Hold |
790
| – | – | ﹤0.01% | 1790 |
|
2024
Q4 | $35.2K | Hold |
790
| – | – | ﹤0.01% | 1758 |
|
2024
Q3 | $35K | Hold |
790
| – | – | ﹤0.01% | 1569 |
|
2024
Q2 | $32.8K | Hold |
790
| – | – | ﹤0.01% | 1576 |
|
2024
Q1 | $34.1K | Sell |
790
-150
| -16% | -$6.47K | ﹤0.01% | 1474 |
|
2023
Q4 | $39.1K | Hold |
940
| – | – | ﹤0.01% | 1292 |
|
2023
Q3 | $37.4K | Hold |
940
| – | – | ﹤0.01% | 1225 |
|
2023
Q2 | $38.5K | Hold |
940
| – | – | ﹤0.01% | 1217 |
|
2023
Q1 | $38.6K | Hold |
940
| – | – | ﹤0.01% | 1170 |
|
2022
Q4 | $38.5K | Hold |
940
| – | – | ﹤0.01% | 1117 |
|
2022
Q3 | $38K | Hold |
940
| – | – | ﹤0.01% | 1059 |
|
2022
Q2 | $39K | Hold |
940
| – | – | ﹤0.01% | 991 |
|
2022
Q1 | $43K | Hold |
940
| – | – | ﹤0.01% | 952 |
|
2021
Q4 | $43K | Hold |
940
| – | – | ﹤0.01% | 886 |
|
2021
Q3 | $45K | Buy |
940
+790
| +527% | +$37.8K | ﹤0.01% | 812 |
|
2021
Q2 | $8K | Hold |
150
| – | – | ﹤0.01% | 1114 |
|
2021
Q1 | $8K | Hold |
150
| – | – | ﹤0.01% | 1044 |
|
2020
Q4 | $8K | Hold |
150
| – | – | ﹤0.01% | 900 |
|
2020
Q3 | $7K | Hold |
150
| – | – | ﹤0.01% | 792 |
|
2020
Q2 | $6K | Hold |
150
| – | – | ﹤0.01% | 841 |
|
2020
Q1 | $5K | Hold |
150
| – | – | ﹤0.01% | 891 |
|
2019
Q4 | $7K | Hold |
150
| – | – | ﹤0.01% | 717 |
|
2019
Q3 | $5K | Hold |
150
| – | – | ﹤0.01% | 694 |
|
2019
Q2 | $6K | Hold |
150
| – | – | ﹤0.01% | 665 |
|
2019
Q1 | $6K | Hold |
150
| – | – | ﹤0.01% | 659 |
|
2018
Q4 | $5K | Hold |
150
| – | – | ﹤0.01% | 624 |
|
2018
Q3 | $7K | Hold |
150
| – | – | ﹤0.01% | 613 |
|
2018
Q2 | $6K | Hold |
150
| – | – | ﹤0.01% | 612 |
|
2018
Q1 | $6K | Hold |
150
| – | – | ﹤0.01% | 571 |
|
2017
Q4 | $7K | Hold |
150
| – | – | ﹤0.01% | 529 |
|
2017
Q3 | $6K | Hold |
150
| – | – | ﹤0.01% | 560 |
|
2017
Q2 | $6K | Buy |
+150
| New | +$6K | ﹤0.01% | 557 |
|